SAN DIEGO – Higher doses of oral semaglutide than the 14-mg/day dose that is currently approved for type 2 diabetes may be additional options for patients […]

SAN DIEGO – Interventions that specifically address diabetes distress can not only improve patient mental health but can also cut costs, according to two new studies in patients […]

SAN DIEGO — Children with type 2 diabetes face a strikingly high complication rate as they age into young adulthood, with an 80% incidence of at […]

CHICAGO – Treatment of hyperthyroidism with surgery or radioactive iodine significantly extends survival compared to antithyroid medication, while surgery raises the risk for obesity, new data […]

SAN DIEGO, CA – Orforglipron, Eli Lilly’s investigational oral daily nonpeptide glucagon-like peptide-1 (GLP-1) agonist that can be taken with or without food, appears comparable with […]

SAN DIEGO, CA — Coadministration of the long-acting amylin analog cagrilintide plus the glucagon-like peptide-1 (GLP-1) agonist semaglutide, dubbed CagriSema, resulted in significantly greater weight loss, along with […]

SAN DIEGO — Weekly tirzepatide injections in adults with type 2 diabetes and overweight or obesity safely led to 12.8%-14.7% in-trial weight loss after 72 weeks […]